Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 369-376

  Dutta Gupta, Sayan ^a,c   Snigdha, D ^a   Mazaira, Gisela I ^d   Galigniana, Mario D ^d,e   Subrahmanyam, C V S ^a   Gowrishankar, N L ^b   Raghavendra, N M ^a  

^a Osmania University   (India)

^b Swami Vivekananda Institute of Pharmaceutical Sciences   (India)

^c JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e Institute of Experimental Biology and Medicine CONICET ^*  (Argentina)

Author keywords

Docking; Hsp90; Malachite green; MTT; Schiff bases

Indexed keywords

2,4 DIHYDROXY BENZALDEHYDE; 4 ((2 BENZOYL 4 CHLOROPHENYLIMINO)METHYL)BENZENE 1,3 DIOL; 4 ((2,3 DICHLOROPHENYLIMINO)METHYL) 6 CHLOROBENZENE 1,3 DIOL; 4 ((2,4 DICHLOROPHENYLIMINO)METHYL) 6 CHLOROBENZENE 1,3 DIOL; 4 ((2,4 DICHLOROPHENYLIMINO)METHYL)BENZENE 1,3 DIOL; 4 ((4 AMINO BENZOPHENONE)METHYL)6 CHLOROBENZENE 1,3 DIOL; 4 ((4 AMINO BENZOPHENONE)METHYL)BENZENE; 4 ((4 HYDROXYPHENYLIMINO)METHYL) 6 CHLOROBENZENE 1,3 DIOL; 4 (5 CHLORO 2,4 DIHYDROXY BENZYLIDENEAMINO)BENZOIC ACID; 4 (DIHYDROXY BENZYLIDIENEAMINO)BENZOIC ACID; 4 CHLORO 6 ((PHENYLIMINO)METHYL)BENZENE 1,3 DIOL; 5 CHLORO 2,4 DIHYDROXY BENZALDEHYDE; ADENOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 90 INHIBITOR; MALACHITE GREEN; SCHIFF BASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; PROTEIN BINDING;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASSAY; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY ASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR DOCKING; MTT ASSAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HYDROGEN BOND; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROGEN BONDING; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN BINDING; SCHIFF BASES;

EID: 84899492835     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.01.003     Document Type: Article

References (50)

1. Nahleh Z., Tfayli A., Najm A., El Sayed A., Nahle Z. Heat shock proteins in cancer: targeting the "chaperones". Future Med Chem 2012, 4:927-935.
2. Dixit A., Verkhivker G.M. Probing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics. PLoS One 2012, 7:e37605.
3. Martins A.S., Davies F.E., Workman P. Inhibiting the molecular evolution of cancer through HSP90. Oncotarget 2012, 3:1054-1056.
4. Didenko T., Duarte A.M., Karagoz G.E., Rudiger S.G. Hsp90 structure and function studied by NMR spectroscopy. Biochim Biophys Acta 2012, 1823:636-647.
5. Vaughan C.K., Piper P.W., Pearl L.H., Prodromou C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic HSP90s. FEBS J 2009, 276:199-209.
6. Neckers L., Trepel J.B. Stressing the development of small molecules targeting Hsp90. Clin Cancer Res 2014, [Epub].
7. Petrikaite V., Matulis D. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application. Medicina (Kaunas) 2011, 47:413-420.
8. Biamonte M.A., Van de Water R., Arndt J.W., Scannevin R.H., Perret D., Lee W.C. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010, 53:3-17.
9. Winssinger N., Fontaine J.G., Barluenga S. Hsp90 inhibition with resorcyclic acid lactones (RALs). Curr Top Med Chem 2009, 9(15):1419-1435.
10. Gopalsamy A., Shi M., Golas J., Vogan E., Jacob J., Johnson M., et al. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. J Med Chem 2008, 51:373-375.
11. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., et al. Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005, 48:4212-4215.
12. Verkhivker G.M., Dixit A., Morra G., Colombo G. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design. Curr Top Med Chem 2009, 9:1369-1385.
13. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., Monks T.J. Role of quinones in toxicology. Chem Res Toxicol 2000, 13:135-160.
14. Tarafder M.T., Kasbollah A., Saravanan N., Crouse K.A., Ali A.M., Tin O.K. S-methyldithiocarbazate and its Schiff bases: evaluation of bondings and biological properties. J Biochem Mol Biol Biophys 2002, 6:85-91.
15. Guo A.J., Xu X.S., Hu Y.H., Wang M.Z., Tan X. Effects of ternary complexes of copper with salicylaldehyde-amino acid Schiff base coordination compounds on the proliferation of BGC823 cells. Chin J Cancer 2010, 29:277-282.
16. Zhao X., Lee P.P.F., Yan Y.K., Chu C.K. Synthesis, crystal structures and cytotoxicities of some transition metal complexes with N-[2-{(pyridin-2-ylmethylidene)amino}ethyl]acetamide. J Inorg Biochem 2007, 101:321-328.
17. Ganguly A., Chakraborty P., Banerjee K., Choudhuri S.K. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. Eur J Pharm Sci 2013, 14:96-99.
18. Sztanke K., Maziarka A., Osinka A., Sztanke M. An insight into synthetic Schiff bases revealing antiproliferative activities in vitro. Bioorg Med Chem 2013, 21:3648-3666.
19. Li X., Li X.Q., Liu H.M., Zhou X.Z., Shao Z.H. Synthesis and evaluation of antitumor activities of novel chiral 1,2,4-triazole Schiff bases bearing gamma-butenolide moiety. Org Med Chem Lett 2012, 2:2191-2258.
20. Kumar S., Matharasi D.P., Gopi S., Sivakumar S., Narasimhan S. Synthesis of cytotoxic and antioxidant Schiff's base analogs of aloin. J Asian Nat Prod Res 2010, 12:360-370.
21. Creaven B.S., Duff B., Egan D.A., Kavanagh K., Rosair G., Thangella V.R., et al. Anticancer and antifungal activity of copper(II) complexes of quinolin-2(1H)-one-derived Schiff bases. Inorganica Chimica Acta 2010, 363:4048-4058.
22. Liu Z.C., Wang B.D., Yang Z.Y., Li Y., Qin D.D., Li T.R. Synthesis, crystal structure, DNA interaction and antioxidant activities of two novel water-soluble Cu2+ complexes derivated from 2-oxo-quinoline-3-carbaldehyde Schiff bases. Eur J Med Chem 2009, 44:4477-4484.
23. Hodnett E.M., Dunn W.J. Cobalt derivatives of Schiff bases of aliphatic amines as antitumor agents. J Med Chem 1972, 15:339.
24. O'Boyle N.M., Knox A.J., Price T.T., Williams D.C., Zisterer D.M., Lloyd D.G., et al. Lead identification of beta-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90. Bioorg Med Chem 2011, 19:6055-6068.
25. Kung P.P., Funk L., Meng J., Collins M., Zhou J.Z., Johnson M.C., et al. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 2008, 18:6273-6278.
26. Jain A.N. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 2007, 21:281-286.
27. de Beer S.B., Vermeulen N.P., Oostenbrink C. The role of water molecules in computational drug design. Curr Top Med Chem 2010, 10:55-66.
28. Kung P.P., Sinnema P.J., Richardson P., Hickey M.J., Gajiwala K.S., Wang F., et al. Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone. Bioorg Med Chem Lett 2011, 21:3557-3562.
29. Yan A., Grant G.H., Richards W.G. Dynamics of conserved waters in human Hsp90: implications for drug design. J R Soc Interface 2008, 6:S199-S205.
30. Karpas Z., Eiceman G.A., Harden C.S., Ewing R.G. On the structure of water-alcohol and ammonia-alcohol protonated clusters. J Am Soc Mass Spectrom 1993, 4:507-512.
31. Gupta S.D., Subrahmanyam C.V.S., Raghavendra N.M. Identification of conserved water molecules and comparative study of docking score in structure-based drug design of HSP 90 inhibitors 2012.
32. Wang R., Lu Y., Wang S. Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 2003, 46:2287-2303.
33. Rarey M., Kramer B., Lengauer T. Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J Comput Aided Mol Des 1997, 11:369-384.
34. Kroemer R.T. Structure-based drug design: docking and scoring. Curr Protein Pept Sci 2007, 8:312-328.
35. Wang R., Lu Y., Fang X., Wang S. An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J Chem Inf Comput Sci 2004, 44:2114-2125.
36. Cheng T., Li X., Li Y., Liu Z., Wang R. Comparative assessment of scoring functions on a diverse test set. J Chem Inf Model 2009, 49:1079-1093.
37. Mendelson W.L., Hayden S. Preparation of 2,4-dihydroxybenzaldehyde by the Vilsmeier-Haack reaction. Synth Comm 1996, 26:603-610.
38. Hopkins C.Y., Chisholm M.J. Chlorination by aqueous sodium hypochlorite. Can J Res 1946, 24:208-210.
39. Scheibel T., Neuhofen S., Weikl T., Mayr C., Reinstein J., Vogel P.D., et al. ATP binding properties of human Hsp90. J Biol Chem 1997, 272:18608-18613.
40. Rowlands M., McAndrew C., Prodromou C., Pearl L., Kalusa A., Jones K., et al. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit. J Biomol Screen 2010, 15:279-286.
41. Harder K.W., Owen P., Wong L.K., Aebersold R., Clark-Lewis I., Jirik F.R. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides. Biochem J 1994, 298:395-401.
42. Avila C., Kornilayev B.A., Blagg B.S. Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem 2006, 14:1134-1142.
43. Rowlands M.G., Newbatt Y.M., Prodromou C., Pearl L.H., Workman P., Aherne W. High-throughput screening assay for inhibitors of heat shock protein 90 ATPase activity. Anal Biochem 2004, 327:176-183.
44. Sylvester P.W. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 2011, 716:157-168.
45. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988, 48:4827-4833.
46. Marshall N.J., Goodwin C.J., Holt S.J. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Growth Regul 1995, 5:69-84.
47. Refat M.S., El-Deen I.M., Ibrahim H.K., El-Ghool S. Synthesis and spectroscopic studies of some transition metal complexes of a novel Schiff base ligands derived from 5-phenylazo-salicyladehyde and o-amino benzoic acid. Spectrochim Acta A Mol Biomol Spectrosc 2006, 65:1208-1220.
48. Upadhyay K.K., Kumar A., Upadhyay S., Mishra P.C. Synthesis, characterization, structural optimization using density functional theory and superoxide ion scavenging activity of some Schiff bases. J Mol Struc 2008, 873:5-16.
49. Liu X., Yan Z., Huang L., Guo M., Zhang Z., Guo C. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin- beta1/focal adhesion kinase/c-Src signaling pathway. Oncol Rep 2011, 25:1343-1351.
50. van Brussel J.P., van Steenbrugge G.J., Romijn J.C., Schroder F.H., Mickisch G.H. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999, 35:664-671.